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Abstract Myoepithelial carcinoma (MCA) is a rare malig-
nancy of salivary glands that was included in the WHO Clas-
sification of Head and Neck Tumors in 1991.MCA has shown
a broad spectrum of clinical outcomes, but attempts to identify
prognostic markers for this malignancy have not resulted in
significant progress. Conventional histopathological charac-
teristics such as tumour grade, nuclear atypia, mitotic index
and cell proliferation have failed to predict the outcome of
MCA. In this study, we reviewed the histopathology of 19
cases of MCA focusing on nuclear atypia, mitotic count, tu-
mour necrosis, nerve and vascular invasion and occurrence of
a pre-existing pleomorphic adenoma in connection to the
MCA. Histopathological characteristics and clinical informa-
tion were correlated with the immunohistochemical
expression of cell cycle proteins including c-Myc, p21,
Cdk4 and Cyclin D3. The proportion of tumour cells immu-
noreactive for these markers and their intensity of staining
were correlated with clinical information using logistic regres-
sion, Kaplan-Meier and Cox regression. Using logistic regres-
sion analysis, cytoplasmic c-Myc expression was associated
with the occurrence of metastases (P=0.019), but limitations
of semi-quantitation of immunostaining and the limited num-
ber of cases preclude definitive conclusions. Our data show
that the occurrence of tumour necrosis predicts poor disease-
free survival in MCA (P=0.035).
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Introduction
Myoepithelial carcinoma (MCA) of salivary glands comprises
less than 2% of salivary gland carcinomas. These malignancies
are almost exclusively composed of cells with myoepithelial
differentiation. They arise de novo or develop in a pre-existing
pleomorphic adenoma or benign myoepithelioma (benign
myoepithelial adenoma) [1]. MCA represents the malignant
counterpart of benign myoepithelioma, the differential diagno-
sis being based predominantly on the presence or absence of
invasive growth. MCA is a well-established malignancy but its
clinical behaviour varies [1–5], and attempts to identify clini-
cally useful indicators of MCA prognosis have not been
successful.
The cell cycle comprises a complex array of proteins, which
interact to control cell proliferation. Regulation of expression of
genes encoding cell cycle proteins includes activity of check-
point proteins such as cyclins and cyclin-dependent kinases,
which ensure that the cell divides only after errors occurred
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during replication of the genome have been corrected. If not,
the cell is kept in a senescent state or will undergo apoptosis [6].
Disruptions in a variety of cell cycle regulators have been re-
ported in cancer. The significance of aberrations in checkpoint
proteins seems to depend on the context in which they occur.
The histogenesis and genetic and epigenetic alterations in any
particular malignancy play an important role in how cell cycle
aberrations affect tumour behaviour [7].
Some of the key proteins in cell cycle regulation include c-
myc, p21, Cdk4 and Cyclin D3.MYC gene encodes a nuclear
phosphoprotein that serves as a DNA-binding factor activat-
ing or repressing the transcription of a large number of genes
[8]. Furthermore, MYC regulates many cellular processes in-
cluding chromatin structure, mRNA translation, DNA replica-
tion and biogenesis of ribosomes [9]. In many cancers, MYC
aberrations lead to its constitutive activation [8]. Of the many
target genes ofMYC, CDK4 and CYCLIN D1 have important
roles in the cell cycle. Both of them phosphorylate RB, leading
to cell cycle progression and enhanced proliferation [6]. In
addition, MYC may downregulate CDK inhibitors such as
P15, P21 and P27, which contributes to cell cycle progression
in early and mid-G1 [6, 10]..
In an attempt to identify prognostic factors for MCA, we
reviewed the clinical and histopathological characteristics of
19 MCAs and studied expression of cell cycle proteins.
Materials and methods
Nineteen cases of MCA were retrieved from the files of the
Department of Pathology, University of Helsinki, Helsinki,
Finland (eight cases) and four from other hospitals in Finland
and Toronto General Hospital, University Health Network,
Toronto, Canada (seven cases). All cases fulfilled the diagnos-
tic histopathological criteria of MCA according to the WHO
Classification of Head and Neck Tumours (2005). In addition,
the diagnoses were confirmed by immunohistochemistry
using a panel of markers for myoepithelial differentiation
(calponin, alpha-smooth muscle actin, smooth muscle myosin
heavy chain, p63, CD10, CK14). Pure myoepithelial differen-
tiation was unequivocally identified in all cases. Tumour in-
filtration into adjacent salivary gland and/or other tissues was
the criterion confirming malignancy.
Clinical data and follow-up information were obtained from
hospital records. Tissue sections (5 μm) were deparaffinized and
subjected to microwave-induced epitope retrieval in 0.01 M cit-
rate buffer (pH 6.0) for 20 min. The specimens were then incu-
bated in a solution of 3 % hydrogen peroxide in methanol to
block endogenous peroxidase. For staining with monoclonal an-
tibodies, the avidin-biotin-peroxidase complex technique
(Vectastain®, Vector laboratories) was used. For staining with
polyclonal antibodies, a dextran polymer conjugated two-step
visualization system was used (Envision®, Dako). Sections were
incubated with the antibodies overnight at +4 °C (Table 1). Pos-
itive controls for each antibody were used as suggested by their
suppliers. Negative controls were obtained by replacing the pri-
mary ant ibody with the DAKO REAL® diluent .
Aminoethylcarbazolewas used as chromogen. The sectionswere
counterstained with Mayer´s haematoxylin and visualized using
a Nikon D80 light microscope.
The intensity of the immunoreactivity was scored semi-
quantitatively as negative (0), weak (1) and strong staining
(2). In addition, the extent of staining for p21 and Cdk4 was
scored. For p21, if fewer than 10% of the nuclei were positive,
the sample was scored as 1, and if more than 10 % of the
nuclei were positive, the score was 2. For Cdk4, if fewer than
50 % of the nuclei were positive, the score was 1, and if over
50 % of the nuclei were positive, the score was 2.
The results were analysed using logistic regression,
Kaplan-Meier and Cox regression. The variables included in-
tensity of cytoplasmic staining for c-Myc; intensity of nuclear
staining for c-Myc; intensity of staining for Cyclin D3, p21
and Cdk4; extent of staining for p21 and Cdk4 and index of
staining for p21 and Cdk4. These parameters were correlated
with tumour size, TNM stage, primary or secondary nature of
the tumour and the presence or absence of metastases. The
clinical data of the patient at last follow-up were used as the
endpoint. In Kaplan-Meyer analysis, the follow-up times were
used for survival analysis.
A literature search for clinicopathological series of MCA
was carried out in PubMed. The five largest series with alto-
gether 144 cases of MCA with clinical and histopathological
data were used as reference for our study (Table 2). We consid-
ered the diagnostic terms myoepithelial carcinoma and malig-
nant myoepithelioma as synonyms. These published cases were
studied in order to compare outcome of patients with MCA ex-
pleomorphic adenoma and de novo MCA. Metastases and re-
currences were used as parameters of clinical outcome.
Results
Clinical information
The clinical data are summarized in Table 2. There were nine
male and ten female patients with a mean age of 54.9 years
Table 1 Antibodies
Antibody Clonality Dilution, titer 1 Source
c-myc Monoclonal 150 BD
p21 Monoclonal 50 Calbiochem
Cdk4 Polyclonal 700 Santa Cruz
Biotechnology
Cyclin D3 Monoclonal 100 Vector
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(range 28 to 78 years). MCAwas localized in 12 patients in the
parotid gland, in four in the submandibular gland, in two in the
hard palate and in one in the buccal mucosa. Of the cases, 12
were de novo MCAs and seven were MCAs ex-pleomorphic
adenoma. Tumour size varied from less than 2 cm to more than
4 cm. At the time of diagnosis, none of the patients showed
metastases. All MCAs were removed surgically, and ten patients
received postoperative radiotherapy, while one patient had also
chemotherapy. Follow-up information was available for 12 cases
(mean 50.7 months, range 2 to 178 months). Of the patients,
seven presented with a recurrence of the primary tumour, and
four had metastatic disease. At the end of follow-up, three pa-
tients had died of the disease and 15 were alive without evidence
of disease. Of the four patients with metastatic disease, two had
MCA ex-pleomorphic adenoma as primary tumour.
Histopathological features
Two basic growth patterns were seen: a multinodular pattern and
a diffuse sheet-like pattern. The multinodular growth pattern was
more prevalent (Fig. 1a). Several cell types were observed in
MCAs, and a mixture of two cell types with one being more
prevalent was seen in almost all tumours.MostMCAs contained
the epithelioid cell type (eight cases) (Fig. 1b). A mostly clear
cell type was found in three tumours (Fig. 1c) while two were
mostly plasmacytoid (Fig. 1d) and four others showed a mostly
spindle cell type (Fig. 1e). TwoMCAs contained more than two
cell types, none of which predominated. Most of the tumours
presented some nuclear pleomorphism, while five cases showed
marked nuclear atypia. Only one case presented mild atypia.
Large areas of tumour necrosis were seen in four MCAs
(Fig. 1f), while the other tumours showed none. Perineural tu-
mour invasion was observed in two MCAs.
Tumour-related extracellular matrix was usually composed
of hyalinized eosinophilic collagenous materials (ten cases)
(Fig. 1d) with fibrillar morphology. Three MCAs had a
myxoid matrix, characterized by loose gelatinous clear-
bluish substance, and three other tumours showed a mixture
of the components described above. Two MCAs presented a
scanty tumour matrix. Occurrence of squamous, chondroid
and osseous metaplasia was seen in three, one and two cases,
respectively. The histological features of our MCAs are sum-
marized in Table 3.
Immunohistochemistry
Immunohistochemical results are shown in Table 4 and Fig. 2.
Staining for c-Myc was observed both in tumour tissue and
adjacent normal salivary gland (Fig. 2a). Tumour cells often
showed strong staining in the cytoplasm with no apparent
nuclear staining (Fig. 2b). Nuclear staining was detected in
only a few tumour cells, except in spindle cell MCAs where
a large proportion of tumour cells presented nuclear staining.
In normal tissues, prominent nuclear staining for c-Myc was
Table 2 Clinical information
Case
no.
Age
(years)/
sex
Primary
site
TNM Treatment Recurrence Metastases Follow-
up
(months)
1 57/M SUB T1N0M0 Sx, RT Yes Yes, lungs 42
2 67/M P T1N0M0 Sx, ND No No 3
3 55/F SUB T1N0M0 Sx, ND, RT No No 23
4 28/M P T1N0M0 Sx, ND No No 17
5 61/M UL+CH T2N0M0 Sx, ND No No 31
6 55/F P T1N0M0 Sx, ND, RT, CT Yes Yes, lungs 31
7 30/M P T2N0M0 Sx No No 82
8 51/F P T3N0M0 Sx, ND No No 9
9 67/F P T2N0M0 Sx, ND No No 2
10 71/M P T4N0M0 Sx, ND, RT Yes No 12
11 60/M P T2N0M0 Sx, ND, RT No No 21
12 68/F SUB T2N0M0 Sx, RT Yes No 47
13 78/F HP T1N0M0 Sx No No 19
14 43/F HP T1N0M0 Sx No No 63
15 62/M SUB T2N0M0 Sx No No 84
16 70/F P T4aN0M0 Sx, ND, RT Yes Yes, multiple 5
17 28/F P T4N0M0 Sx Yes No 164
18 52/M P T1N0M0 Sx, RT Yes Yes, multiple 26
19 41/F P T4aN0M0 Sx, RT No No 178
P parotid, SUB submandibular gland, HP hard palate, UL+CH upper lip+cheek, TB tongue base
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detected in acinar cells while only few myoepithelial cells
were positive. Epithelial and myoepithelial cells of normal
salivary ducts showed diffuse cytoplasmic staining for c-
Myc while only a few nuclei were positive.
Staining for Cdk4 was characterized by intense nuclear
immunoreactivity in tumour cells, while only very few
positive cells were detected in the adjacent normal salivary
gland (Fig. 2c). However, the percentage of positive cells
in the different MCAs varied considerably (Fig. 2d). Nu-
clear staining for p21 was seen in some tumour cells,
while several MCAs were negative for p21 (Fig. 2e). Ad-
jacent normal salivary gland cells were negative for p21.
Nuclear staining for Cyclin D3 was found in ten MCAs.
The number of positive cells varied between individual
tumours, but they often had foci with a high number of
positive nuclei interspersed with areas with few or no
positive nuclei (Fig. 2f). Adjacent normal salivary gland
was consistently negative for Cyclin D3.
Statistical analyses
The results of immunohistochemical staining are summarized
in Table 3. In logistic regression analysis, a significant corre-
lation was seen between the intensity of cytoplasmic staining
for c-Myc and the occurrence of metastases (P=0.019). A
score of 3 for the intensity of cytoplasmic staining for c-Myc
was accompanied by a frequency of metastases 24 times
higher than for a score of ≤2. No other statistically significant
correlations were found between the immunohistochemical
results and clinical parameters.
In search of other large series in the literature, we found 48
cases ofMCA ex-pleomorphic adenoma with follow-up infor-
mation, of which 24 patients showed no evidence of disease
(NED) and 24 were alive with disease (AWD) or dead of
disease (DOD) [2, 4, 5, 11, 12]. Of the 36 de novoMCA cases,
23 were with NED and 13 DOD or AWD (Table 5). Some
cases were lost to follow-up or the authors did not separate de
Fig. 1 Histological
characteristics of MCA. a.
Multinodular growth pattern. b.
Nests of epithelioid MCA cells
invading adjacent fat tissue. c.
Clear tumour cells displayed in
sheets and small lobules. d.
Plasmacytoid cells with
interspersed hyalinized matrix. e.
Spindle cell MCA (left) and
reminiscent PA (right) f.
Epithelioid tumour cells showing
necrosis (bottom left)
308 Virchows Arch (2016) 468:305–312
novo cases from carcinoma ex-pleomorphic adenoma, which
we did not include.
Discussion
This is a collaborative study on 19 cases of MCA. Histopath-
ological characteristics and clinical information of these pa-
tients were correlated with the expression of cell cycle pro-
teins including c-Myc, p21, Cdk4 and Cyclin D3. Our follow-
up information suggests that MCA is a malignant tumour with
variable behaviour. Of our 19 patients, four (21 %) developed
metastases, and three of these (16 %) died of disease. Recur-
rences developed in seven of our patients (37 %) and 12
(63 %) had no evidence of disease.
Our results suggest a somewhat worse clinical outcome
than in the series reported by Kane et al. 2010 (51 cases/
follow-up available for 18 patients), since these authors found
no patients who had died from this disease and 68 % who
developed recurrences [3]. On the other hand, our results sug-
gest a better clinical outcome than the series of Savera et al.
2000 (25 cases, follow-up available for 17 patients), of which
29 % of patients died of disease, 47 % developed recurrences
and 59% showed no evidence of disease [2]. In our series, this
was 37 and 63 %, suggesting somewhat better treatment re-
sults in our patients (Table 5). In the largest series recently
Table 3 Histopathological characteristics of 19 cases of myoepithelial carcinoma
Case no. Cell type Tumour matrix History of
benign tumour
Evidence of
benign tumour
Mitosis
score
Nuclear atypia Necrosis Nerve
inv
Vascular
inv
1 Epithelioid Hyalinized No No 3 2 + − +
2 Clear cell Hyalinized No PA 1 1 + − −
3 Spindle Hyalinized No No 1 2 − − +
4 Mixed Hyalinized No ? 1 2 − − −
5 Epithelioid Hyalinized No PA 1 2 + + −
6 Epithelioid Myxoid/hyalinized Yes ? 2 1 + − −
7 Spindle Scanty No No 1 2 − − −
8 Mixed Myxoid/hyalinized No No 2 2 − − −
9 Clear cell Hyalinized Yes PA 1 2 − − −
10 Epithelioid Myxoid/hyalinized Yes PA 2 2 − − −
11 Epithelioid Hyalinized No No 1 2 − − −
12 Clear cell Hyalinized No No 3 2 + + −
13 Plasmacytoid Myxoid No No 2 2 − − −
14 Spindle Scanty No PA 3 3 − − −
15 Epithelioid Hyalinized No No 2 2 − + +
16 Epithelioid Hyalinized Yes PA 2 2 + − −
17 Plasmacytoid Hyalinized No No 1 1 − − −
18 Spindle Myxoid No PA 2 3 − − −
19 Epithelioid Myxoid No No 1 1 − − −
Mitotic index=1–3; atypia index=1–3
PA pleomorphic adenoma, Nerve inv nerve invasion, Vascular inv vascular invasion
Table 4 Immunohistochemical profiles and occurrence of metastases
Case no. c-Myc Cyclin D3 p21-index Cdk4-index Metastases
1 C3N1 0 2 0 Lungs
2 C2N1 1 2 2 No
3 C1N1 0 2 2 No
4 C3N1 2 2 3 No
5 C2N1 2 4 2 No
6 C3N1 2 5 3 Lungs
7 C1N1 0 2 3 No
8 C1N1 1 3 3 No
9 C2N1 0 2 3 No
10 C2N1 0 2 3 No
11 C2N2 1 4 4 No
12 C2N2 0 2 4 No
13 C2N2 1 4 4 No
14 C2N3 0 3 4 No
15 C3N1 1 3 4 No
16 C2N1 2 3 4 Multiple
17 C2N1 1 2 2 No
18 C3N0 0 0 2 Multiple
19 C3N0 1 2 3 No
C cytoplasmic staining; N nuclear staining; index=i+e, where i=staining
intensity and e=extent of staining
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published by Kong et al. (48 cases, follow-up available for 44
patients), nearly one third of the patients developed distant
metastasis. [4].
Tumour necrosis was the only histopathological parameter
in our MCA cases that correlated with poor disease-free sur-
vival. Patients in this group showed 12 times higher occur-
rence of recurrence, metastasis or death of disease when com-
pared to MCA patients of which the tumour did not show
necrosis. Tumour necrosis is easy to evaluate as pathological
marker and a well-established marker of poor prognosis in
sarcomas, renal cell carcinoma [13–15] as well as a marker
of malignancy, e.g. in uterine leiomyoma [16]. A relation be-
tween tumour necrosis, cytological atypia, mitotic rate and
clinical outcome has been observed before [2, 10], but these
parameters were not validated as prognostic markers in MCA.
Only recently tumour necrosis has been correlated with re-
duced disease-free survival in MCA [4, 5]. In our study, only
tumour necrosis predicted poor outcome, while cytological
atypia and mitotic rate did not. Of all clinical and histopatho-
logical parameters in our study, tumour necrosis was the only
parameter significantly correlated with disease-free survival
Fig. 2 Immunohistochemical
staining in MCA. a, b. c-Myc
immunoreactivity. Note
conspicuous cytoplasmic staining
in neoplastic cells and nuclear
staining in NSG cells. c.
Predominant nuclear positivity in
neoplastic cells for cdk4. d. A
different area of the same tumour
observed in (c), showing a higher
number of cdk4-positive cells. e.
Strong nuclear p21 staining. f.
Foci showing a high number of
positive Cyclin D3 nuclei
interspersed with areas with few
or no positive nuclei
Table 5 Outcome of MCA in literature
MCA
ex-PA
MCA
ex-PA,
MCA
de novo,
MCA
de novo,
NED AWD/DOD NED AWD/DOD
Nagao et al. 4 2 1 2
Savera et al. 5 6 2 4
Di Palma et al. 2 3 2 3
Kong et al. 13 13 18 4
Present study 2 2 13 2
Total 26 26 36 15
PA pleomorphic adenoma, NED no evidence of disease, AWD alive with
disease, DOD dead of disease, NED no evidence of disease
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(DFS). Interestingly, rearrangements involving Ewing’s sarco-
ma breakpoint region 1 (EWSR1) have recently been found in
a subset of MCA presenting clear cell morphology and fre-
quent tumour necrosis. The presence of such rearrangements
is indicative of worse clinical behaviour [5]. In our study, two
of three cases with clear cell morphology exhibited tumour
necrosis (Table 3).
A wide variety of tumour cell morphologies (clear cell, epi-
thelioid, plasmacytoid, spindle cell) was seen in ourMCA cases.
Similar to previous studies, the prevalence of any of these cell
types did not correlate with clinical outcome.We did not find any
histopathological appearance different from those described in
previous series, except from stellate cell morphology reported by
Kane&Bagwan [3], whichwe have not found in our series. This
stellate morphology might be a misinterpretation in case of a
tumour presenting a mixture of plasmacytoid and spindle cells.
Frequent nerve and vascular invasion was reported by Nagao
et al. [11], Savera et al. [2] and Kong et al. [4], but we found it
in only two cases. The reason for this may be that the previous
studies used serial sectioning of their tumours.
The significance of a pre-existing pleomorphic adenoma for
the clinical outcome of MCA has been debated in the literature
[2, 4, 11, 12]. Seven of our cases (37 %) showed a pre-existing
pleomorphic adenoma, and two additional cases (10 %) had
appearances suggesting but not conclusive of a pre-existing
pleomorphic adenoma. We did not find any difference between
the outcome of cases with pre-existing pleomorphic adenoma
and de novoMCA cases, which is in agreement with previously
published reports [2, 11]. Nevertheless, together with the cases
reported in the literature, our data indicate worse clinical out-
come for cases containing a pre-existing pleomorphic adenoma.
This differs from the previous report of Di Palma et al. [12] but
is in agreement with results reported by Kong et al. [4]. Inter-
estingly, Katabi et al. reported that a carcinoma ex-pleomorphic
adenoma MCA recurred more often than other types of carci-
noma ex-pleomorphic adenoma [17], and in our series, all cases
that developed metastasis also recurred.
Our findings indicate that cytoplasmic expression of c-Myc
in MCA cells correlates with the occurrence of metastases.
MYC amplification or overexpression is seen in 9 to 48 % of
head and neck squamous cell carcinomas [18] and in over
40 % of gastric carcinomas [19]. In addition, evidence sug-
gests that c-Myc not only acts as a transcription factor enhanc-
ing translation of many downstream genes but also is involved
in chromatin remodelling and ribosome biogenesis and as
such implicated in proliferation, differentiation and cell
growth [9]. In MCA cells, we detected c-Myc expression in
the cytoplasm, but usually not in nuclei. This may imply that
in MCA, the role of c-Myc is different from that of a classic
transcription factor, perhaps related to the multitude of other
processes that can be regulated by c-Myc. However, limita-
tions of semi-quantitation of immunostaining and the limited
number of cases preclude definitive conclusions. Additional
studies are needed to clarify the role of cytoplasmic c-Myc
protein in MCA. In view of our present results on c-Myc, we
note that copy number gain has been found in MCA in prox-
imity to the MYC gene at 8q24.21 [20].
Overexpression of p21, cdk4 and Cyclin D3 was seen in a
few of our cases but no significant correlations were
established. This does not preclude a cell cycle stimulating
effect of overexpression of these molecules in individual cases.
Disruption of the retinoblastoma (Rb) pathway has been
reported in many types of salivary gland tumour, including
MCA [21]. Using immunohistochemistry, Vekony et al. [22]
observed increased expression of p16/ARF in MCA com-
pared to normal salivary gland. MCA also shows overexpres-
sion of p53 [11, 22]. We hypothesize that malignant transfor-
mation of myoepithelial cells may require deregulation of the
p16/ARF pathway and inactivation of p53. The Rb, p53, p16
and c-Myc pathways may be involved in regulation of the cell
cycle during pathogenesis of MCA.
In conclusion, clinical behaviour in MCA is variable and
identification of prognostic factors has been challenging. In
our series of MCA, the presence of tumour necrosis correlated
with worse disease-free survival, while a pre-existing pleo-
morphic adenoma did not influence clinical outcome.
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